Amgen (AMGN) ended the recent trading session at $322.67, demonstrating a +1.12% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.13%.

Federman & Sherwood investigates Amgen, Inc. for data breach. Amgen became aware of a cybersecurity incident that involved one of their service providers, Sirva Relocation, LLC and its parent company ...

Barron’s 2024 Healthcare Roundtable panelists make the case for 21 healthcare companies of all stripes, including Humana, ...

On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Cantor initiated Amgen (AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech company’s ...

Hippocratic AI is developing a generative AI model that aims to help providers complete non-diagnostic and patient-facing tasks ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This summer, Microsoft was considering a big potential AI revamp of its important 365 software suite. Now, the company has ...

compared with placebo. AstraZeneca and Amgen are also planning a Phase III for Tezspire in COPD.

Shares of Amgen Inc. AMGN advanced 1.99% to $319.10 Thursday, on what proved to be an all-around great trading session for ...